Showing 15 posts of 16 posts found.


Mylan looks to hit Teva where it hurts, eyeing slow-release MS treatment

April 11, 2018
Research and Development, Sales and Marketing Copaxone, Mapi Pharma, Mylan, Teva, biotech, drugs, pharma, pharmaceutical

Mylan has taken several steps recently that seem intended to hit sales of its big rivals on their key products, …


Mylan receives shock approval of Teva blockbuster

October 5, 2017
Sales and Marketing Copaxone, Mylan, Teva, biotech, drugs, pharma, pharmaceutical

Mylan had been knocked back by the FDA in its quest to have its generic version of Copaxone approved earlier …


US Congressmen accuse Teva of price hikes over 1,000%

August 21, 2017
Sales and Marketing Copaxone, Teva, life sciences, medicine, multiple sclerosis, pharma, pharmaceutical, price hiking

A pair of US Congressmen have fired allegations at Israeli drugmaker Teva accusing the firm of hiking the price of …

Pfizer plant receives FDA warning letter for contamination of medicine

March 1, 2017
Manufacturing and Production Copaxone, Mylan, Pfizer, Teva, generics

The FDA has issued a warning letter to Pfizer after inspectors discovered that the plant did not protect properly against …


Teva sets out to delay generic competitor to Copaxone

October 31, 2016
Sales and Marketing Copaxone, Teva, Teva Pharmaceutical, generics

Teva Pharmacetuical, the Israel-based pharmaceutical company, submitted a document to the FDA on 30 October; the document outlines the differences …


Teva loses patent protection on lucrative MS treatment

August 25, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Copaxone, Mylan, Teva, multiple sclerosis

Teva’s stock plunged 3% after a US agency ruled that two of its patents related to multiple sclerosis drug Copaxone …

Scotland flag

Cancer and MS drugs approved in Scotland

December 9, 2015
Sales and Marketing Celgene, Copaxone, Novartis, SMC, Scottish Medicines Consortium, Tevaq, ceritinib, glatiramer acetate, lenalidomide, lung cancer, multiple myeloma, multiple sclerosis, revlimis, zykadia

The Scottish Medicines Consortium (SMC) has approved three new treatments for lung cancer, multiple sclerosis and multiple myeloma, from Novartis, …

Teva image

US Supreme Court backs Teva in Copaxone patent case

January 28, 2015
Sales and Marketing Copaxone, Momenta Pharmaceuticals, Mylan, Natco Pharma, Teva

Teva has won a US Supreme Court judgement allowing it to continue marketing its multiple sclerosis drug Copaxone without challenge …

Takeda image

Takeda trials Teva Parkinson’s drug in Japan

January 9, 2015
Sales and Marketing Azilect, CHMP, Copaxone, Parkinson's, Takeda, rasagiline

Takeda has begun late stage trials for Teva’s Parkinson’s disease drug Azilect in Japan, with the hopes of bringing the …

Teva image

Teva to ditch R&D in cancer and women’s health

October 6, 2014
Manufacturing and Production, Research and Development, Sales and Marketing Copaxone, FDA, MS, R&D, Teva, cuts, generics

Teva will stop research into oncology and women’s health in order to cut costs and focus more on generics and …

Teva image

Teva considers up to 27 plant closures

May 13, 2014
Manufacturing and Production, Sales and Marketing Copaxone, Nerventra, Teva, cuts, generics

Teva is to close 11 of its production sites, with another 16 facilities ‘under evaluation’, as part of a major …

Teva image

Teva under investigation for marketing practices

February 12, 2014
Sales and Marketing Azilect, Copaxone, Teva, fines, generics

Teva Pharmaceuticals is under investigation by US authorities for sales and marketing activity around two of its drugs – including …


High-dose Copaxone the right medicine for Teva

January 29, 2014
Research and Development, Sales and Marketing Biogen, Copaxone, FDA, MS, Mylan, Teva

The FDA has approved a high-dose version of Teva’s multiple sclerosis drug Copaxone which will help the firm offset approaching …

Levin image

Teva boss quits over Board struggles

October 31, 2013
Medical Communications, Sales and Marketing Copaxone, Levin, Teva, generics

Teva’s president and chief executive Dr Jeremy Levin has unexpectedly quit as the firm struggles with staff cuts and management …

Teva image

Teva to axe 5,000 jobs in savings drive

October 11, 2013
Manufacturing and Production, Research and Development, Sales and Marketing Copaxone, FDA, Teva, cuts

The world’s largest generic drugmaker Teva will cut around 5,000 jobs from its global workforce as it looks to speed-up …

Latest content